
  
    
      
        Introduction_NNP
        Fetuses_NNP of_IN diabetic_JJ mothers_NNS with_IN uncontrolled_JJ blood_NN
        glucose_NN levels_NNS tend_VBP to_TO be_VB hyperglycemic_JJ and_CC
        hyperinsulinemic_JJ [_NN 1_CD ]_NN ._. An_DT increased_VBN incidence_NN of_IN neonatal_NN
        respiratory_JJ distress_NN syndrome_NN (_( RDS_NNP )_) has_VBZ been_VBN observed_VBN in_IN
        infants_NNS of_IN diabetic_JJ mothers_NNS [_NN 1_CD ]_NN ._. RDS_NNP is_VBZ caused_VBN by_IN
        inadequate_JJ amounts_NNS of_IN pulmonary_JJ surfactant_NN due_JJ to_TO delayed_VBN
        lung_NN development_NN [_NN 2_CD ]_NN ._. It_PRP has_VBZ been_VBN proposed_VBN that_IN high_JJ
        insulin_NN levels_NNS can_MD delay_VB lung_NN development_NN in_IN the_DT fetus_NN of_IN
        the_DT diabetic_JJ mother_NN [_NN 3_CD ]_NN ._.
        Surfactant_NNP ,_, a_DT lipoprotein_NN comprised_VBN of_IN phospholipids_NNS
        (_( ~_NN 80_CD %_NN )_) ,_, cholesterol_NN (_( ~_NN 10_CD %_NN )_) ,_, and_CC proteins_NNS (_( ~_NN 10_CD %_NN )_) ,_, functions_NNS
        to_TO reduce_VB surface_NN tension_NN and_CC prevents_VBZ alveolar_NN collapse_NN at_IN
        end_NN expiration_NN [_NN 4_CD ]_NN ._. The_DT surfactant-associated_JJ proteins_NNS
        (_( SP_NNP )_) A_DT ,_, B_NNP ,_, C_NNP and_CC D_NNP ,_, which_WDT are_VBP required_VBN for_IN proper_JJ
        surfactant_NN function_NN ,_, are_VBP developmentally_RB and_CC hormonally_RB
        regulated_VBN [_NN 4_CD ]_NN ._. We_PRP ,_, and_CC others_NNS ,_, have_VBP shown_VBN that_IN the_DT SP-A_NNP
        levels_NNS in_IN the_DT amniotic_JJ fluid_NN of_IN diabetic_JJ mothers_NNS are_VBP
        significantly_RB decreased_VBN [_NN 1_CD ]_NN ._. Low_NNP SP-A_NNP levels_NNS in_IN amniotic_JJ
        fluid_JJ have_VBP been_VBN correlated_JJ with_IN an_DT increased_VBN incidence_NN of_IN
        neonatal_NN RDS_NNP [_NN 5_CD ]_NN ._. Our_PRP$ previous_JJ studies_NNS have_VBP shown_VBN that_DT
        insulin_NN down-regulates_JJ SP-A_NNP mRNA_NN and_CC protein_NN levels_NNS in_IN
        human_JJ lung_NN epithelial_NN cells_NNS in_IN a_DT concentration_NN and_CC
        time-dependent_JJ manner_NN via_IN an_DT inhibition_NN of_IN gene_NN
        transcription_NN [_NN 6_CD 7_CD ]_NN ._.
        Insulin_NNP transduces_NNS its_PRP$ cellular_JJ signal_NN in_IN most_JJS cell_NN
        types_NNS via_IN two_CD signaling_VBG pathways_NNS ,_, i_NNP ._. e_SYM ._. ,_, the_DT p_NN 44_CD /_NN 42_CD
        mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NNP )_) pathway_NN and_CC the_DT
        phosphatidylinositol_NN 3_CD -_: kinase_NN (_( PI_NNP 3_CD -_: kinase_NN )_) pathway_NN [_NN 8_CD ]_NN ._.
        Insulin_NNP initially_RB binds_NNS to_TO the_DT insulin_NN receptor_NN causing_VBG
        autophosphorylation_NN of_IN the_DT β-subunit_JJ of_IN the_DT receptor_NN [_NN 8_CD ]_NN
        ._. The_DT protein_NN kinase_NN domain_NN of_IN the_DT β-subunit_JJ then_RB
        phosphorylates_NNS tyrosine_NN residues_NNS in_IN insulin_NN receptor_NN
        substrate_NN (_( IRS_NNP )_) -_: 1_CD ,_, IRS-_NNP 2_CD ,_, IRS-_NNP 3_CD ,_, or_CC Shc_NNP ,_, which_WDT then_RB
        activates_NNS the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP signaling_VBG cascade_NN [_NN 8_CD ]_NN ._. PD_NNP 98059_CD
        is_VBZ a_DT cell_NN permeable_JJ ,_, non-competitive_JJ ,_, reversible_JJ inhibitor_NN
        of_IN MAPK_NNP /_NN extracellular_NN signal-regulated_JJ kinase_NN kinase_NN (_( MEK_NNP )_) ,_,
        a_DT protein_NN kinase_NN upstream_RB of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP [_NN 9_CD ]_NN ._. Tyrosine_NNP
        phosphorylated_JJ IRS_NNP also_RB activates_NNS the_DT PI_NNP 3_CD -_: kinase_NN pathway_NN [_NN
        8_CD 10_CD ]_NN ._. There_RB are_VBP at_IN least_JJS three_CD ,_, well-characterized_JJ
        inhibitors_NNS of_IN the_DT PI_NNP 3_CD -_: kinase_NN pathway_NN ,_, i_NNP ._. e_SYM ._. ,_, wortmannin_NN ,_,
        LY_NNP 294002_CD ,_, and_CC rapamycin_NN [_NN 11_CD 12_CD 13_CD ]_NN ._. Wortmannin_NNP and_CC
        LY_NNP 294002_CD block_VB the_DT activation_NN of_IN PI_NNP 3_CD -_: kinase_NN itself_PRP [_NN 11_CD 12_CD
        ]_NN ,_, while_IN rapamycin_NN prevents_VBZ the_DT phosphorylation_NN of_IN a_DT
        downstream_JJ effector_NN in_IN the_DT pathway_NN ,_, p_NN 70_CD S_NNP 6_CD kinase_NN [_NN 13_CD ]_NN
        ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP used_VBD two_CD experimental_JJ models_NNS ,_, a_DT
        human_JJ lung_NN adenocarcinoma_NN cell_NN line_NN ,_, NCI-H_NNP 441_CD ,_, and_CC human_JJ
        fetal_JJ lung_NN explants_NNS ._. H_NNP 441_CD cells_NNS resemble_VBP bronchiolar_NN
        epithelial_NN Clara_NNP cells_NNS in_IN phenotype_NN and_CC produce_VB both_DT SP-A_NNP
        and_CC SP-B_NNP mRNA_NN and_CC protein_NN [_NN 14_CD ]_NN ._. The_DT hormonal_NN regulation_NN
        of_IN SP-A_NNP and_CC SP-B_NNP gene_NN expression_NN in_IN H_NNP 441_CD cells_NNS is_VBZ similar_JJ
        to_TO that_DT observed_VBD in_IN differentiated_JJ type_NN II_NNP cells_NNS in_IN human_JJ
        fetal_JJ lung_NN explants_NNS [_NN 6_CD 7_CD 15_CD 16_CD ]_NN ._. We_PRP treated_VBD H_NNP 441_CD cells_NNS
        with_IN the_DT four_CD inhibitors_NNS of_IN signal_NN transduction_NN :_:
        wortmannin_NN ,_, LY_NNP 294002_CD ,_, rapamycin_NN and_CC PD_NNP 98059_CD ,_, to_TO elucidate_NN
        which_WDT signaling_VBG pathways_NNS are_VBP activated_VBN when_WRB insulin_NN
        inhibits_NNS SP-A_NNP gene_NN expression_NN ._. To_TO confirm_VB these_DT results_NNS ,_, we_PRP
        repeated_VBD key_JJ experiments_NNS with_IN insulin_NN and_CC the_DT signal_NN
        transduction_NN inhibitors_NNS using_VBG human_JJ fetal_JJ lung_NN explants_NNS ._. We_PRP
        then_RB examined_VBD the_DT levels_NNS and_CC phosphorylation_NN state_NN of_IN key_JJ
        enzymes_NNS in_IN the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP and_CC PI_NNP 3_CD -_: kinase_NN signaling_VBG
        pathways_NNS ._. We_PRP found_VBD that_DT insulin_NN probably_RB inhibits_NNS SP-A_NNP gene_NN
        expression_NN in_IN lung_NN epithelial_NN cells_NNS via_IN the_DT
        rapamycin-sensitive_JJ PI_NNP 3_CD -_: kinase_NN pathway_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cell_NNP and_CC explant_NN cultures_NNS
          A_DT human_JJ lung_NN adenocarcinoma_NN cell_NN line_NN ,_, NCI-H_NNP 441_CD ,_, was_VBD
          maintained_VBN 
          in_IN vitro_NN in_IN monolayer_NN culture_NN in_IN
          10_CD %_NN fetal_JJ bovine_JJ serum_NN in_IN the_DT presence_NN of_IN penicillin_NN (_( 100_CD
          U_NNP /_NN ml_NN )_) ,_, streptomycin_NN (_( 100_CD μg_NN /_NN ml_NN )_) and_CC fungizone_NN (_( 0_CD ._. 25_CD
          μg_NN /_NN ml_NN )_) at_IN 37_CD °_NN C_NNP in_IN a_DT 5_CD %_NN CO_NNP 
          2_CD atmosphere_NN [_NN 14_CD ]_NN ._. Culture_NNP media_NNS
          were_VBD changed_VBN every_DT 3_CD days_NNS and_CC cells_NNS were_VBD passed_VBN (_( 1_CD :_: 4_LS )_)
          weekly_JJ ._. For_IN the_DT inhibitor_NN experiments_NNS ,_, the_DT H_NNP 441_CD cells_NNS
          were_VBD grown_VBN until_IN ~_NN 80_CD %_NN confluent_NN ,_, then_RB incubated_JJ in_IN
          serum-free_JJ media_NNS for_IN 24_CD hours_NNS prior_RB to_TO an_DT experiment_NN ._. The_DT
          cultured_JJ cells_NNS were_VBD subsequently_RB exposed_VBN to_TO fresh_JJ
          serum-free_JJ media_NNS and_CC pretreated_JJ for_IN 30_CD -_: 60_CD minutes_NNS with_IN
          either_DT control_NN media_NNS that_WDT contained_VBD the_DT vehicle_NN for_IN the_DT
          inhibitors_NNS (_( dimethyl_NN sulphoxide_NN )_) or_CC with_IN media_NNS that_WDT
          contained_JJ wortmannin_NN (_( 5_CD -_: 200_CD nM_NN )_) ,_, LY_NNP 294002_CD (_( 2_CD -_: 50_CD μM_NN )_) ,_,
          rapamycin_NN (_( 1_CD -_: 100_CD nM_NN )_) ,_, or_CC PD_NNP 98059_CD (_( 2_CD ._. 5_LS -_: 25_CD μM_NN )_) ._. After_IN
          pretreatment_NN ,_, either_CC insulin_NN (_( 2_CD ._. 5_LS μg_NN /_NN ml_NN )_) or_CC vehicle_NN
          (_( dilute_VB HCl_NNP )_) was_VBD added_VBN for_IN an_DT additional_JJ 12_CD -_: 16_CD hours_NNS ._.
          Experiments_NNS were_VBD repeated_VBN three_CD to_TO five_CD times_NNS unless_IN
          otherwise_RB noted_VBD ._.
          Human_JJ lung_NN tissue_NN was_VBD obtained_VBN from_IN mid-tremester_JJ
          abortuses_NNS (_( 15_CD -_: 21_CD weeks_NNS old_JJ )_) ,_, dissected_VBN free_JJ from_IN blood_NN
          vessels_NNS and_CC conducting_VBG airways_NNS ,_, then_RB minced_JJ with_IN a_DT
          sterile_JJ razor_NN blade_NN into_IN ~_NN 1_CD mm_NN 3_CD explants_NNS [_NN 6_CD ]_NN ._. The_DT
          explants_NNS were_VBD maintained_VBN on_IN lens_NN paper-covered_JJ stainless_JJ
          steel_NN grids_NNS at_IN the_DT air-media_JJ interface_NN in_IN Waymouth_NNP 's_POS
          media_NNS at_IN 37_CD °_NN C_NNP and_CC 5_CD %_NN CO_NNP 
          2_CD for_IN 6_CD days_NNS ._. The_DT media_NNS were_VBD changed_VBN
          daily_RB ._. On_IN the_DT last_JJ day_NN of_IN culture_NN ,_, explants_NNS were_VBD
          pretreated_JJ with_IN signal_NN transduction_NN inhibitors_NNS ,_, either_CC
          wortmannin_NN ,_, rapamycin_NN or_CC PD_NNP 98059_CD ,_, for_IN 30_CD -_: 60_CD min_NN and_CC then_RB
          further_RBR treated_VBN with_IN insulin_NN (_( 2_CD ._. 5_LS μg_NN /_NN ml_NN )_) for_IN 12_CD -_: 24_CD hours_NNS ._.
          Experiments_NNS were_VBD performed_VBN in_IN duplicate_VB and_CC were_VBD repeated_VBN
          twice_RB ._.
        
        
          Reagents_NNP
          Porcine_NNP insulin_NN was_VBD purchased_VBN from_IN Calbiochem_NNP (_( San_NNP
          Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, wortmannin_NN ,_, LY_NNP 294002_CD ,_, and_CC rapamycin_NN were_VBD
          purchased_VBN from_IN Sigma-_NNP Aldrich_NNP Company_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP ,_,
          USA_NNP )_) ,_, and_CC PD_NNP 98059_CD was_VBD purchased_VBN from_IN New_NNP England_NNP Biolabs_NNP
          (_( Beverly_NNP ,_, MA_NNP ,_, USA_NNP )_) ._. Insulin_NNP was_VBD prepared_VBN as_IN 2_CD ._. 5_CD mg_NN /_NN ml_NN
          stock_NN solution_NN in_IN ~_NN 0_CD ._. 01_CD N_NNP HCl_NNP ,_, aliquoted_JJ and_CC stored_VBD at_IN
          -_: 80_CD °_NN C_NNP ._. Wortmannin_NNP ,_, LY_NNP 294002_CD ,_, rapamycin_NN and_CC PD_NNP 98059_CD were_VBD
          reconstituted_JJ in_IN dimethyl_NN sulphoxide_NN as_IN 1_CD mM_NN ,_, 50_CD mM_NN ,_, 50_CD
          μM_NN and_CC 10_CD mM_NN stock_NN solutions_NNS ,_, respectively_RB ,_, and_CC stored_VBD at_IN
          -_: 80_CD °_NN C_NNP in_IN aliquots_NNS ._. Insulin_NNP causes_VBZ a_DT time-_NN and_CC
          dose-dependent_JJ inhibition_NN of_IN SP-A_NNP gene_NN expression_NN with_IN
          maximum_NN effect_NN at_IN 0_CD ._. 25_CD -_: 2_CD ._. 5_LS μg_NN /_NN ml_NN (_( ~_NN 40_CD to_TO 400_CD nM_NN )_) [_NN 7_CD ]_NN ._.
          In_IN order_NN to_TO achieve_VB a_DT maximal_NN inhibitory_NN effect_NN of_IN
          insulin_NN ,_, we_PRP used_VBD a_DT concentration_NN of_IN 2_CD ._. 5_CD μg_NN /_NN ml_NN in_IN the_DT
          present_JJ study_NN ._.
        
        
          Transcription_NNP run-on_JJ assay_NN
          Nuclear_JJ isolation_NN ,_, transcription_NN elongation_NN reactions_NNS
          and_CC hybridizations_NNS were_VBD performed_VBN as_IN described_VBN previously_RB
          with_IN minor_JJ modifications_NNS [_NN 7_CD ]_NN ._. Subconfluent_NNP H_NNP 441_CD cells_NNS
          were_VBD incubated_JJ in_IN serum-free_JJ media_NNS for_IN 24_CD hours_NNS and_CC then_RB
          exposed_VBN to_TO media_NNS plus_CC either_CC vehicle_NN or_CC insulin_NN (_( 2_CD ._. 5_LS
          μg_NN /_NN ml_NN )_) for_IN an_DT additional_JJ 1_CD ,_, 4_CD ,_, 8_CD and_CC 24_CD hours_NNS ._. The_DT cells_NNS
          were_VBD then_RB rinsed_JJ and_CC trypsinized_JJ ,_, and_CC nuclei_NN from_IN control_NN
          and_CC treated_VBN cells_NNS were_VBD harvested_VBN ._. The_DT transcription_NN
          elongation_NN reaction_NN was_VBD performed_VBN with_IN 20_CD ×_NN 10_CD 6_CD nuclei_NN ._.
          Labeled_NNP ,_, newly_RB synthesized_JJ RNA_NNP was_VBD then_RB isolated_VBN and_CC
          purified_JJ from_IN the_DT nuclei_NN ._. Nytran_NNP membranes_NNS with_IN
          immobilized_JJ cDNAs_NNS for_IN the_DT BlueScript_NNP vector_NN ,_, human_JJ SP-A_NNP
          and_CC human_JJ α-actin_JJ were_VBD prehybridized_JJ in_IN 1_CD ml_NN of_IN buffer_NN
          (_( 50_CD %_NN formamide_NN ,_, 5_CD X_NNP SSC_NNP ,_, 5_CD X_NNP Denhardt_NNP 's_POS solution_NN ,_, 100_CD
          μg_NN /_NN ml_NN denatured_JJ herring_NN sperm_NN ,_, 0_CD ._. 1_CD %_NN SDS_NNP )_) for_IN 4_CD hours_NNS at_IN
          45_CD °_NN C_NNP and_CC then_RB hybridized_JJ to_TO the_DT labeled_VBN RNAs_NNP (_( 6_CD ×_NN 10_CD 6_CD cpm_NN
          in_IN the_DT presence_NN of_IN 500_CD units_NNS of_IN RNasin_NNP )_) in_IN duplicate_VB for_IN
          an_DT additional_JJ 60_CD hours_NNS ._. Afterwards_RB ,_, the_DT hybridized_JJ
          membranes_NNS were_VBD washed_VBN twice_RB in_IN 0_CD ._. 2_CD X_NNP SSC_NNP with_IN 0_CD ._. 1_CD %_NN SDS_NNP at_IN
          55_CD °_NN C_NNP for_IN 1_CD hour_NN ,_, once_RB in_IN 2_CD X_NNP SSC_NNP at_IN 55_CD °_NN C_NNP for_IN 15_CD min_NN ,_, once_RB
          in_IN 2_CD X_NNP SSC_NNP with_IN 10_CD μg_NN /_NN ml_NN RNase_NNP A_DT at_IN 37_CD °_NN C_NNP for_IN 30_CD min_NN and_CC
          then_RB rinsed_JJ twice_RB in_IN 2_CD X_NNP SSC_NNP at_IN room_NN temperature_NN for_IN 15_CD
          min_NN ._. Membranes_NNP were_VBD exposed_VBN to_TO a_DT Storage_NNP Phosphor_NNP Screen_NNP
          (_( Molecular_NNP Dynamics_NNP ,_, San_NNP Francisco_NNP ,_, CA_NNP ,_, USA_NNP )_) for_IN 3_CD -_: 5_CD
          days_NNS ,_, scanned_JJ using_VBG a_DT PhosphorImager_NNP (_( Molecular_NNP Dynamics_NNP )_)
          and_CC data_NNS quantitated_JJ using_VBG Quantity_NNP One_CD software_NN (_( Bio-_NNP Rad_NNP
          Laboratories_NNPS ,_, Hercules_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Northern_JJ blot_NN analysis_NN
          Northern_JJ blot_NN analysis_NN was_VBD used_VBN to_TO semi-quantitate_JJ
          SP-A_NNP mRNA_NN levels_NNS ._. H_NNP 441_CD cells_NNS were_VBD harvested_VBN and_CC total_JJ RNA_NNP
          isolated_VBD as_IN described_VBN previously_RB [_NN 16_CD ]_NN ._. Equal_NNP amounts_NNS
          of_IN total_JJ RNA_NNP from_IN each_DT condition_NN were_VBD separated_JJ on_IN
          agarose_NN gels_NNS ,_, transferred_VBN to_TO Nytran-plus_NNP membranes_NNS
          (_( Schleicher_NNP and_CC Schuell_NNP ,_, Keene_NNP ,_, NH_NNP ,_, USA_NNP )_) ,_, and_CC
          subsequently_RB hybridized_JJ with_IN a_DT radiolabeled_JJ human_JJ SP-A_NNP
          cDNA_NN ._. Radioactive_NNP bands_NNS were_VBD detected_VBN using_VBG X-_NNP ray_NN film_NN
          after_IN a_DT 1_CD -_: 4_CD hour_NN exposure_NN with_IN an_DT intensifier_NN screen_NN at_IN
          -_: 70_CD °_NN C_NNP ._. The_DT relative_JJ intensity_NN of_IN the_DT reactive_JJ bands_NNS was_VBD
          estimated_VBN by_IN densitometry_NN and_CC corrected_VBN for_IN RNA_NNP loading_NN
          as_IN described_VBN previously_RB [_NN 16_CD ]_NN ._.
          To_TO perform_VB a_DT northern_JJ blot_NN analysis_NN of_IN the_DT human_JJ fetal_JJ
          lung_NN explant_NN samples_NNS ,_, 4_CD μg_NN of_IN total_JJ RNA_NNP from_IN each_DT
          condition_NN were_VBD immobilized_JJ on_IN Nytran-plus_NNP membranes_NNS (_( 0_CD ._. 2_LS
          μm_NN ,_, Schleicher_NNP and_CC Schuell_NNP )_) in_IN triplicate_NN in_IN denaturing_VBG
          solution_NN (_( 66_CD %_NN formamide_NN ,_, 7_CD ._. 9_CD %_NN formaldehyde_NN ,_, 26_CD mM_NN MOPS_NNP
          buffer_NN ,_, pH_NN 7_CD ._. 0_CD ,_, 1_CD ._. 3_CD mM_NN EDTA_NNP ,_, 0_CD ._. 066_CD M_NNP sodium_NN acetate_NN )_)
          using_VBG a_DT slot_NN blot_NN apparatus_NN ._. The_DT membranes_NNS were_VBD then_RB
          processed_VBN for_IN northern_JJ blot_NN analysis_NN as_IN described_VBN above_IN ._.
          In_IN addition_NN ,_, 10_CD μg_NN of_IN total_JJ RNA_NNP from_IN each_DT explant_NN sample_NN
          were_VBD separated_JJ on_IN agarose_NN gels_NNS to_TO ensure_VB the_DT quality_NN of_IN
          the_DT RNA_NNP samples_NNS and_CC to_TO correct_VB for_IN RNA_NNP loading_NN ._.
        
        
          Immunoblotting_NNP
          The_DT total_JJ amount_NN and_CC phosphorylation_NN states_NNS of_IN p_NN 44_CD /_NN 42_CD
          MAPK_NNP and_CC p_NN 70_CD S_NNP 6_CD kinase_NN were_VBD assessed_VBN using_VBG immunoblot_NN
          analysis_NN according_VBG to_TO the_DT methods_NNS described_VBN by_IN Sharma_NNP and_CC
          coworkers_NNS [_NN 17_CD ]_NN ._. H_NNP 441_CD cells_NNS were_VBD incubated_JJ in_IN
          serum-free_JJ media_NNS for_IN 24_CD hours_NNS then_RB exposed_VBN to_TO fresh_JJ
          control_NN media_NNS plus_CC either_CC insulin_NN (_( 2_CD ._. 5_LS μg_NN /_NN ml_NN )_) or_CC vehicle_NN
          for_IN 15_CD min_NN ,_, 30_CD min_NN ,_, 2_CD hours_NNS or_CC 16_CD hours_NNS ._. Control_NNP and_CC
          treated_VBN cells_NNS were_VBD rinsed_JJ twice_RB with_IN PBS_NNP and_CC then_RB
          incubated_JJ with_IN 1_CD ml_NN of_IN lysis_NNS buffer_NN (_( 10_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN
          7_CD ._. 4_CD ,_, 150_CD mM_NN NaCl_NNP ,_, 1_CD mM_NN EDTA_NNP ,_, 1_CD mM_NN EGTA_NNP ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 50_CD mM_NN NaF_NNP ,_, 5_CD mM_NN sodium_NN
          pyrophosphate_NN ,_, 0_CD ._. 2_CD mM_NN sodium_NN orthovanadate_NN ,_, 2_CD μg_NN /_NN ml_NN
          aprotinin_NN ,_, 2_CD μg_NN /_NN ml_NN leupeptin_NN ,_, 10_CD %_NN glycerol_NN ,_, 1_CD %_NN Triton_NNP
          X-_NNP 100_CD ,_, 0_CD ._. 5_CD %_NN NP-_NNP 40_CD ,_, 1_CD mM_NN phenylmethylsulfonyl_NN fluoride_NN )_)
          for_IN 1_CD hour_NN with_IN shaking_VBG at_IN 4_CD °_NN C_NNP ._. Equal_NNP amounts_NNS of_IN protein_NN
          lysates_NNS from_IN each_DT condition_NN in_IN 1_CD X_NNP sample_NN buffer_NN (_( 125_CD mM_NN
          Tris-_NNP HCl_NNP ,_, pH_NN 6_CD ._. 8_CD ,_, 1_CD %_NN β-mercaptoethanol_JJ ,_, 2_CD %_NN SDS_NNP ,_, 5_CD %_NN
          glycerol_NN ,_, 0_CD ._. 003_CD %_NN bromphenol_NN blue_JJ )_) were_VBD separated_JJ on_IN 7_CD ._. 5_CD
          or_CC 10_CD %_NN polyacrylamide_NN gels_NNS and_CC subsequently_RB transferred_VBN
          to_TO nitrocellulose_NN membranes_NNS ._. Immunoblotting_NNP of_IN membranes_NNS
          for_IN phospho-_NN MAPK_NNP (_( extracellular_NN signal-regulated_JJ kinase_NN
          [_NN Erk_NNP ]_NN 1_CD /_NN 2_LS )_) was_VBD performed_VBN using_VBG a_DT Phospho-_NNP MAPK_NNP Antibody_NNP
          Sampler_NNP kit_NN (_( Cell_NNP Signaling_NNP ,_, Beverly_NNP ,_, MA_NNP ,_, USA_NNP )_) according_VBG
          to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. The_DT phospho-_NN MAPK_NNP
          antibody_NN recognizes_VBZ dual_JJ phosphorylated_JJ Erk_NNP 1_CD and_CC Erk_NNP 2_CD at_IN
          Thr_NNP 202_CD /_NN Tyr_NNP 204_CD ._. Total_JJ p_NN 44_CD /_NN 42_CD MAPK_NNP was_VBD detected_VBN with_IN rabbit_NN
          polyclonal_NN anti-_NN MAPK_NNP (_( Erk_NNP 1_LS )_) (_( Santa_NNP Cruz_NNP Biotechnology_NNP ,_,
          Inc_NNP ._. ,_, Santa_NNP Cruz_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS ._. Membranes_NNP were_VBD then_RB
          incubated_JJ with_IN a_DT secondary_JJ antibody_NN ,_, horseradish_NN
          peroxidase-conjugated_JJ anti-rabbit_JJ IgG_NNP (_( 1_CD :_: 4000_CD ,_, ICN_NNP
          Biomedical_NNP Research_NNP Products_NNPS ,_, Costa_NNP Mesa_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT
          reactive_JJ bands_NNS were_VBD detected_VBN using_VBG chemiluminescence_NN
          (_( ECL_NNP ,_, Amersham_NNP Pharmacia_NNP Biotech_NNP ,_, Piscataway_NNP ,_, NJ_NNP ,_, USA_NNP )_) ._.
          Immunoblotting_NNP experiments_NNS for_IN the_DT detection_NN of_IN total_JJ and_CC
          phosphorylated_JJ p_NN 70_CD S_NNP 6_CD kinase_NN were_VBD performed_VBN using_VBG a_DT
          PhosphoPlus_NNP p_NN 70_CD S_NNP 6_CD Kinase_NNP (_( Thr_NNP 389_CD ,_, Thr_NNP 421_CD /_NN Ser_NNP 424_CD )_)
          Antibody_NNP kit_NN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS
          (_( Cell_NNP Signaling_NNP )_) ._.
        
        
          Lactate_NNP dehydrogenase_NN assay_NN
          Lactate_NNP dehydrogenase_NN (_( LDH_NNP )_) activity_NN was_VBD determined_VBN in_IN
          cell_NN culture_NN media_NNS ._. Pyruvate_NNP conversion_NN into_IN lactate_NN was_VBD
          measured_VBN in_IN 0_CD ._. 2_CD M_NNP Tris-_NNP HCl_NNP (_( pH_NN 7_CD ._. 2_LS )_) buffer_NN in_IN the_DT
          presence_NN of_IN sodium_NN pyruvate_NN (_( 0_CD ._. 037_CD mg_NN /_NN ml_NN ,_, Fisher_NNP
          Scientific_NNP ,_, Fair_NNP Lawn_NNP ,_, NJ_NNP ,_, USA_NNP )_) and_CC the_DT reduced_VBN form_NN of_IN
          β-nicotinamide_JJ adenine_NN dinucleotide_NN (_( 0_CD ._. 057_CD mg_NN /_NN ml_NN ,_, Sigma_NNP )_)
          at_IN 22_CD °_NN C_NNP by_IN measuring_VBG absorbance_NN at_IN 340_CD nm_NN ._. LDH_NNP activity_NN
          was_VBD determined_VBN as_IN the_DT rate_NN of_IN decrease_NN in_IN absorbency_NN per_IN
          min_NN using_VBG a_DT standard_JJ curve_NN for_IN lactate_NN hydrogenase_NN (_( 2_CD -_: 40_CD
          mU_NN ,_, L-_NNP lactic_JJ dehydrogenase_NN ,_, porcine_NN muscle_NN ,_, Sigma_NNP )_) ._. LDH_NNP
          activity_NN in_IN the_DT media_NNS samples_NNS was_VBD normalized_JJ to_TO controls_NNS ,_,
          which_WDT were_VBD made_VBN equal_JJ to_TO one_CD ._.
        
        
          Statistical_NNP analysis_NN
          All_DT experiments_NNS were_VBD repeated_VBN at_IN least_JJS three_CD times_NNS
          unless_IN otherwise_RB stated_VBN ._. Student_NNP 's_POS t-test_JJ or_CC one-way_JJ
          analysis_NN of_IN variance_NN (_( ANOVA_NNP )_) followed_VBN by_IN Dunnett_NNP 's_POS test_NN
          was_VBD used_VBN to_TO estimate_VB the_DT statistical_JJ significance_NN of_IN the_DT
          results_NNS [_NN 18_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Lactate_NNP dehydrogenase_NN assay_NN
          LDH_NNP activity_NN was_VBD measured_VBN in_IN media_NNS obtained_VBN from_IN
          control_NN H_NNP 441_CD cells_NNS and_CC cells_NNS treated_VBN with_IN the_DT various_JJ
          signal_NN transduction_NN inhibitors_NNS ._. LDH_NNP activity_NN was_VBD not_RB
          different_JJ from_IN controls_NNS in_IN cells_NNS treated_VBN for_IN 12_CD to_TO 16_CD
          hours_NNS with_IN either_DT 200_CD nM_NN wortmannin_NN ,_, 5_CD μM_NN LY_NNP 294002_CD ,_, 20_CD nM_NN
          rapamycin_NN ,_, or_CC 10_CD μM_NN PD_NNP 98059_CD (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Effects_NNPS of_IN signal_NN transduction_NN inhibitors_NNS and_CC
          insulin_NN on_IN SP-A_NNP mRNA_NN levels_NNS
          Wortmannin_NNP is_VBZ a_DT fungal_NN metabolite_NN that_WDT is_VBZ a_DT relatively_RB
          selective_JJ inhibitor_NN of_IN PI_NNP 3_CD -_: kinase_NN with_IN a_DT half-maximal_JJ
          inhibition_NN (_( IC_NNP 
          50_CD )_) less_JJR than_IN 5_CD nM_NN [_NN 11_CD ]_NN ._. In_IN the_DT
          wortmannin_NN experiments_NNS ,_, media_NNS were_VBD changed_VBN every_DT 2_CD hours_NNS
          for_IN a_DT total_NN of_IN 12_CD hours_NNS in_IN all_DT of_IN the_DT conditions_NNS because_IN
          wortmannin_NN is_VBZ unstable_JJ in_IN solution_NN at_IN physiological_JJ pH_NN [_NN
          19_CD ]_NN ._. The_DT shorter_JJR incubation_NN time_NN with_IN insulin_NN in_IN the_DT
          wortmannin_NN experiments_NNS resulted_VBD in_IN a_DT decreased_VBN inhibitory_NN
          effect_NN of_IN insulin_NN ,_, i_NNP ._. e_SYM ._. ,_, an_DT ~_NN 22_CD %_NN inhibition_NN of_IN SP-A_NNP mRNA_NN
          levels_NNS (_( Fig_NNP ._. 1_LS A_DT )_) versus_CC an_DT ~_NN 40_CD %_NN inhibition_NN observed_VBD after_IN
          the_DT 16_CD -_: hour_NN incubation_NN used_VBN in_IN the_DT experiments_NNS with_IN
          rapamycin_NN and_CC PD_NNP 98059_CD (_( Fig_NNP ._. 1_LS Band_NNP 1_CD C_NNP )_) ._. Wortmannin_NNP ,_, added_VBD
          alone_RB ,_, did_VBD not_RB significantly_RB alter_VB SP-A_NNP mRNA_NN levels_NNS at_IN
          any_DT concentration_NN tested_VBN (_( Fig_NNP ._. 1_LS A_DT )_) ._. However_RB wortmannin_NN ,_,
          at_IN concentrations_NNS of_IN 5_CD -_: 200_CD nM_NN ,_, abolished_VBD the_DT
          insulin-mediated_JJ inhibition_NN of_IN SP-A_NNP mRNA_NN levels_NNS at_IN all_DT
          concentrations_NNS tested_VBN (_( 5_CD -_: 200_CD nM_NN ,_, Fig_NNP ._. 1_LS A_DT )_) ._.
          To_TO confirm_VB the_DT inhibitory_NN effect_NN of_IN wortmannin_NN on_IN
          insulin_NN action_NN ,_, a_DT structurally_RB different_JJ PI_NNP 3_CD -_: kinase_NN
          inhibitor_NN ,_, LY_NNP 294002_CD ,_, was_VBD used_VBN ._. LY_NNP 294002_CD is_VBZ a_DT competitive_JJ
          inhibitor_NN of_IN the_DT PI_NNP 3_CD -_: kinase_NN ATP-binding_NNP site_NN ,_, with_IN an_DT IC_NNP
          
          50_CD =_SYM 1_CD ._. 4_CD μM_NN 
          in_IN vitro_NN [_NN 12_CD ]_NN ._. LY_NNP 294002_CD ,_, added_VBD
          alone_RB ,_, decreased_VBD SP-A_NNP mRNA_NN levels_NNS at_IN concentrations_NNS
          greater_JJR than_IN 10_CD μM_NN (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, 2_CD μM_NN
          LY_NNP 294002_CD abolished_VBD the_DT inhibitory_NN effects_NNS of_IN insulin_NN ,_, but_CC
          did_VBD not_RB affect_VB basal_NN SP-A_NNP mRNA_NN levels_NNS ._. In_IN the_DT control_NN
          group_NN ,_, insulin_NN significantly_RB decreased_VBD SP-A_NNP mRNA_NN levels_NNS
          to_TO 57_CD ±_NN 11_CD %_NN of_IN control_NN levels_NNS ,_, however_RB ,_, in_IN presence_NN of_IN 2_CD
          μM_NN LY_NNP 294002_CD ,_, insulin_NN only_RB decreased_VBD SP-A_NNP mRNA_NN levels_NNS to_TO
          87_CD ±_NN 15_CD %_NN of_IN control_NN levels_NNS versus_CC 99_CD ±_NN 3_CD %_NN of_IN control_NN
          levels_NNS in_IN samples_NNS treated_VBN with_IN LY_NNP 294002_CD alone_RB (_( mean_VB ±_NN SE_NNP ,_,
          n_NN =_SYM 4_CD ,_, n_NN indicates_VBZ the_DT number_NN of_IN independent_JJ
          experiments_NNS )_) ._.
          Rapamycin_NNP inhibits_NNS activation_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN ,_, a_DT
          downstream_JJ effector_NN in_IN the_DT PI_NNP 3_CD -_: kinase_NN signaling_VBG pathway_NN
          [_NN 13_CD ]_NN ._. Rapamycin_NNP forms_VBZ a_DT complex_NN with_IN FK_NNP 506_CD -_: binding_JJ
          protein_NN 12_CD and_CC this_DT complex_JJ blocks_VBZ the_DT kinase_NN activity_NN of_IN
          mTOR_NN (_( mammalian_JJ target_NN of_IN rapamycin_NN )_) ,_, a_DT kinase_NN upstream_RB
          of_IN p_NN 70_CD S_NNP 6_CD kinase_NN [_NN 20_CD ]_NN ._. The_DT IC_NNP 
          50_CD for_IN p_NN 70_CD S_NNP 6_CD kinase_NN inhibition_NN by_IN
          rapamycin_NN is_VBZ ~_NN 0_CD ._. 04_CD -_: 0_CD ._. 4_LS nM_NN [_NN 13_CD ]_NN ._. When_WRB added_VBD alone_RB at_IN
          concentrations_NNS of_IN 1_CD -_: 100_CD nM_NN ,_, rapamycin_NN did_VBD not_RB affect_VB SP-A_NNP
          mRNA_NN levels_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) ._. However_RB ,_, rapamycin_NN abolished_VBD the_DT
          insulin-mediated_JJ inhibition_NN of_IN SP-A_NNP gene_NN expression_NN in_IN a_DT
          dose-dependent_JJ manner_NN ._.
          To_TO examine_VB whether_IN the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP pathway_NN mediates_NNS
          insulin_NN signaling_VBG in_IN the_DT H_NNP 441_CD cells_NNS ,_, PD_NNP 98059_CD ,_, an_DT
          inhibitor_NN of_IN the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP pathway_NN ,_, was_VBD used_VBN [_NN 9_CD ]_NN ._.
          PD_NNP 98059_CD binds_NNS to_TO the_DT dephosphorylated_JJ form_NN of_IN MEK_NNP and_CC
          prevents_VBZ its_PRP$ activation_NN 
          in_IN vivo_NN with_IN an_DT IC_NNP 
          50_CD of_IN 10_CD μM_NN [_NN 9_CD ]_NN ._. PD_NNP 98059_CD ,_, added_VBD
          alone_RB ,_, significantly_RB decreased_VBD SP-A_NNP mRNA_NN levels_NNS in_IN a_DT
          dose-dependent_JJ manner_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. PD_NNP 98059_CD had_VBD no_DT effect_NN on_IN
          the_DT insulin_NN inhibition_NN of_IN SP-A_NNP mRNA_NN levels_NNS ._.
          We_PRP also_RB treated_VBD cultured_JJ human_JJ fetal_JJ lung_NN explants_NNS
          with_IN wortmannin_NN ,_, rapamycin_NN or_CC PD_NNP 98059_CD in_IN the_DT presence_NN or_CC
          absence_NN of_IN insulin_NN ._. Fig_NNP ._. 2_LS shows_VBZ that_DT wortmannin_NN (_( 100_CD nM_NN )_)
          and_CC rapamycin_NN (_( 50_CD nM_NN )_) both_DT abolished_VBD the_DT insulin-mediated_JJ
          inhibition_NN of_IN SP-A_NNP gene_NN expression_NN ._. In_IN agreement_NN with_IN the_DT
          H_NNP 441_CD cells_NNS results_NNS ,_, PD_NNP 98059_CD (_( 2_CD ._. 5_LS -_: 10_CD μM_NN )_) had_VBD no_DT effect_NN on_IN
          the_DT insulin_NN inhibition_NN of_IN SP-A_NNP mRNA_NN while_IN decreasing_VBG
          basal_NN SP-A_NNP mRNA_NN levels_NNS in_IN a_DT dose-dependent_JJ manner_NN when_WRB
          added_VBD alone_RB ._.
        
        
          Transcription_NNP rate_NN of_IN human_JJ SP-A_NNP
          In_IN our_PRP$ previous_JJ studies_NNS ,_, we_PRP have_VBP shown_VBN that_IN insulin_NN
          inhibits_NNS the_DT rate_NN of_IN SP-A_NNP gene_NN transcription_NN after_IN a_DT
          24_CD -_: hour_NN exposure_NN [_NN 7_CD ]_NN ._. In_IN this_DT study_NN ,_, we_PRP evaluated_VBD the_DT
          effects_NNS of_IN insulin_NN on_IN the_DT transcription_NN rate_NN of_IN the_DT human_JJ
          SP-A_NNP and_CC α-actin_JJ genes_NNS at_IN several_JJ time-points_JJ earlier_RBR
          than_IN those_DT used_VBN in_IN our_PRP$ previous_JJ studies_NNS ._. The_DT rate_NN of_IN SP-A_NNP
          gene_NN transcription_NN increased_VBD in_IN a_DT time-dependent_JJ manner_NN
          (_( Fig_NNP ._. 3_LS )_) ._. Insulin_NNP inhibited_VBD human_JJ SP-A_NNP gene_NN transcription_NN
          at_IN every_DT time-point_JJ tested_VBN ,_, even_RB as_RB early_RB as_IN after_IN 1_CD hour_NN
          of_IN insulin_NN treatment_NN ._. Insulin_NNP did_VBD not_RB decrease_VB human_JJ
          α-actin_JJ gene_NN transcription_NN at_IN any_DT time_NN point_NN ._.
        
        
          Phosphorylation-activation_NNP of_IN protein_NN
          kinases_NNS
          Immunoblot_NNP analysis_NN of_IN control_NN and_CC insulin-treated_JJ
          H_NNP 441_CD cells_NNS using_VBG phosphospecific_JJ antibodies_NNS for_IN p_NN 44_CD /_NN 42_CD
          MAPK_NNP and_CC p_NN 70_CD S_NNP 6_CD kinase_NN revealed_VBD that_IN both_DT kinases_NNS were_VBD in_IN
          a_DT partially_RB activated_VBN state_NN at_IN the_DT 15_CD min_NN time_NN point_NN ._. The_DT
          phosphorylation_NN of_IN the_DT protein_NN kinases_NNS in_IN the_DT controls_NNS
          declined_VBD over_IN time_NN and_CC remained_VBD at_IN minimum_JJ levels_NNS after_IN
          30_CD min_NN to_TO 2_CD hours_NNS of_IN incubation_NN ._. We_PRP attribute_VBP this_DT
          partial_JJ activation_NN of_IN the_DT signaling_VBG kinases_NNS to_TO the_DT media_NNS
          change_VBP that_WDT occurred_VBD immediately_RB prior_RB to_TO insulin_NN or_CC
          vehicle_NN addition_NN [_NN 21_CD ]_NN ._.
        
        
          p_NN 44_CD /_NN 42_CD MAPK_NNP
          The_DT total_JJ amount_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP was_VBD equal_JJ and_CC remained_VBD
          level_NN in_IN control_NN and_CC insulin-treated_JJ cells_NNS at_IN all_DT
          time-points_JJ (_( Fig_NNP ._. 4_LS A_DT )_) ._. Insulin_NNP did_VBD not_RB affect_VB p_NN 44_CD /_NN 42_CD MAPK_NNP
          phosphorylation_NN within_IN a_DT 2_CD -_: hour_NN incubation_NN time_NN ,_, but_CC
          significantly_RB decreased_VBD phosphorylation_NN after_IN 16_CD hours_NNS
          (_( Fig_NNP ._. 4_LS B_NNP )_) ._. Densitometric_NNP data_NNS of_IN immunoreactive_JJ bands_NNS of_IN
          phospho-p_JJ 44_CD /_NN 42_CD MAPK_NNP in_IN the_DT presence_NN of_IN insulin_NN were_VBD equal_JJ
          to_TO 0_CD ._. 39_CD ±_NN 0_CD ._. 01_CD for_IN the_DT 16_CD hour_NN time_NN point_NN when_WRB compared_VBN
          to_TO the_DT corresponding_JJ controls_NNS which_WDT were_VBD made_VBN equal_JJ to_TO
          one_CD (_( mean_VB ±_NN SE_NNP ,_, t-test_JJ ,_, p_NN <_NN 0_CD ._. 05_CD ,_, n_NN =_SYM 3_LS )_) ._.
          Since_IN it_PRP is_VBZ possible_JJ that_IN the_DT insulin-mediated_JJ
          stimulation_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP phosphorylation_NN had_VBD ended_VBN
          within_IN a_DT 15_CD min_NN exposure_NN to_TO insulin_NN ,_, we_PRP performed_VBD
          additional_JJ experiments_NNS in_IN order_NN to_TO evaluate_VB the_DT
          possibility_NN of_IN a_DT shorter_JJR time_NN course_NN of_IN insulin_NN action_NN ._.
          Serum-starved_NNP cells_NNS were_VBD incubated_JJ with_IN fresh_JJ serum-free_JJ
          media_NNS for_IN 1_CD hour_NN at_IN 37_CD °_NN C_NNP (_( in_IN order_NN to_TO return_VB the_DT
          phosphorylation_NN levels_NNS of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP to_TO the_DT basal_NN state_NN )_)
          and_CC then_RB treated_VBN with_IN insulin_NN (_( 2_CD ._. 5_LS μg_NN /_NN ml_NN )_) or_CC vehicle_NN for_IN
          5_CD min_NN ._. Insulin_NNP did_VBD not_RB activate_VBP p_NN 44_CD /_NN 42_CD MAPK_NNP within_IN this_DT
          time_NN frame_NN ._. The_DT intensity_NN of_IN the_DT immunoreactive_JJ bands_NNS of_IN
          phospho-p_JJ 44_CD /_NN 42_CD MAPK_NNP from_IN insulin-treated_JJ cells_NNS was_VBD 0_CD ._. 92_CD ±_NN
          0_CD ._. 10_CD relative_JJ to_TO controls_NNS ,_, which_WDT were_VBD made_VBN equal_JJ to_TO one_CD
          (_( data_NNS are_VBP the_DT mean_NN of_IN two_CD experiments_NNS performed_VBN in_IN
          duplicate_VB plus_CC or_CC minus_CC the_DT standard_JJ deviation_NN of_IN the_DT
          mean_NN )_) ._. In_IN order_NN to_TO prove_VB that_DT p_NN 44_CD /_NN 42_CD MAPK_NNP can_MD be_VB
          stimulated_VBN in_IN H_NNP 441_CD cells_NNS by_IN an_DT activator_NN of_IN this_DT kinase_NN ,_,
          some_DT cells_NNS were_VBD also_RB treated_VBN with_IN 10_CD nM_NN 12_CD -_: 
          O_NNP -_: tetradecanoylphorbol-_NN 13_CD -_: acetate_NN
          (_( TPA_NNP )_) ,_, a_DT strong_JJ stimulator_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP in_IN H_NNP 441_CD cells_NNS ,_,
          for_IN 5_CD min_NN [_NN 21_CD ]_NN ._. TPA_NNP caused_VBD an_DT approximately_RB twofold_NN
          increase_NN in_IN p_NN 44_CD /_NN 42_CD MAPK_NNP phosphorylation_NN over_IN control_NN
          levels_NNS ._.
        
        
          p_NN 70_CD S_NNP 6_CD kinase_NN
          The_DT total_JJ amount_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN present_JJ in_IN the_DT cells_NNS
          decreased_VBD during_IN the_DT 16_CD hour_NN incubation_NN period_NN ,_, however_RB ,_,
          there_EX was_VBD no_DT difference_NN in_IN the_DT amount_NN present_JJ in_IN control_NN
          vs_NNS ._. insulin-treated_JJ cells_NNS at_IN any_DT time-point_JJ (_( Fig_NNP ._. 5_LS A_DT )_) ._.
          Fig_NNP ._. 5_LS Bshows_NNP that_IN despite_IN increased_VBN basal_NN p_NN 70_CD S_NNP 6_CD kinase_NN
          phosphorylation_NN ,_, insulin_NN caused_VBD an_DT additional_JJ
          up-regulation_JJ of_IN p_NN 70_CD S_NNP 6_CD kinase_NN on_IN Thr_NNP 389_CD after_IN incubation_NN
          with_IN insulin_NN for_IN 15_CD min_NN to_TO 16_CD hours_NNS ._. Phosphorylation_NNP of_IN
          p_NN 70_CD S_NNP 6_CD kinase_NN on_IN Thr_NNP 389_CD is_VBZ essential_JJ for_IN the_DT activation_NN
          of_IN the_DT kinase_NN [_NN 22_CD ]_NN ._. In_IN the_DT presence_NN of_IN insulin_NN ,_, the_DT
          intensity_NN of_IN the_DT Thr_NNP 389_CD p_NN 70_CD S_NNP 6_CD kinase_NN bands_NNS was_VBD
          significantly_RB increased_VBN after_IN 15_CD min_NN exposure_NN and_CC reached_VBN
          2_CD ._. 02_CD ±_NN 0_CD ._. 31_CD after_IN 15_CD min_NN and_CC 1_CD ._. 36_CD ±_NN 0_CD ._. 17_CD after_IN a_DT 16_CD hour_NN
          incubation_NN period_NN when_WRB compared_VBN to_TO respective_JJ controls_NNS
          which_WDT were_VBD made_VBN equal_JJ to_TO one_CD (_( mean_VB ±_NN SE_NNP ,_, t-test_JJ ,_, p_NN <_NN
          0_CD ._. 05_CD ,_, n_NN =_SYM 4_LS )_) ._. Insulin_NNP also_RB stimulated_VBN the_DT phosphorylation_NN
          of_IN p_NN 70_CD S_NNP 6_CD kinase_NN Thr_NNP 421_CD /_NN Ser_NNP 424_CD at_IN the_DT 30_CD -_: min_NN and_CC 2_CD -_: hour_NN
          incubation_NN times_NNS when_WRB compared_VBN to_TO their_PRP$ respective_JJ
          controls_NNS (_( Fig_NNP ._. 5_LS C_NNP )_) ._.
        
        
          Inhibitors_NNP of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP and_CC p_NN 70_CD S_NNP 6_CD kinase_NN
          PD_NNP 98059_CD caused_VBD a_DT dramatic_JJ decrease_NN in_IN the_DT
          phosphorylation_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP ,_, in_IN the_DT presence_NN or_CC
          absence_NN of_IN insulin_NN (_( Fig_NNP ._. 6_CD A_DT )_) when_WRB compared_VBN to_TO controls_NNS ._.
          Incubation_NNP of_IN cells_NNS with_IN rapamycin_NN did_VBD not_RB affect_VB p_NN 44_CD /_NN 42_CD
          MAPK_NNP phosphorylation_NN in_IN any_DT condition_NN (_( Fig_NNP ._. 6_CD B_NNP )_) ._.
          Rapamycin_NNP completely_RB abolished_VBD the_DT phosphorylation_NN of_IN
          Thr_NNP 389_CD in_IN p_NN 70_CD S_NNP 6_CD kinase_NN in_IN insulin-treated_JJ cells_NNS and_CC also_RB
          abolished_VBD the_DT basal_NN phosphorylation_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN in_IN
          control_NN cells_NNS ,_, at_IN both_DT time_NN points_NNS examined_VBD (_( Fig_NNP ._. 6_CD C_NNP )_) ._.
          Rapamycin_NNP also_RB down_RB regulated_VBN the_DT Thr_NNP 421_CD /_NN Ser_NNP 424_CD
          phosphorylation_NN in_IN p_NN 70_CD S_NNP 6_CD kinase_NN in_IN control_NN and_CC
          insulin-treated_JJ cells_NNS at_IN both_DT time-points_JJ (_( Fig_NNP ._. 6_CD E_NNP )_) ._.
          PD_NNP 98059_CD did_VBD not_RB affect_VB Thr_NNP 389_CD or_CC Thr_NNP 421_CD /_NN Ser_NNP 424_CD
          phosphorylation_NN in_IN p_NN 70_CD S_NNP 6_CD kinase_NN in_IN insulin-treated_JJ cells_NNS
          at_IN either_DT time_NN point_NN ,_, but_CC slightly_RB decreased_VBD their_PRP$
          phosphorylation_NN when_WRB added_VBD alone_RB (_( Figs_NNP ._. 6_CD Dand_NNP 6_CD F_NN )_) ._.
        
      
      
        Discussion_NNP
        Nothing_NN is_VBZ known_VBN about_IN the_DT relationship_NN between_IN
        signaling_VBG pathways_NNS and_CC the_DT regulation_NN of_IN SP-A_NNP gene_NN
        expression_NN by_IN insulin_NN ._. In_IN contrast_NN ,_, insulin_NN signal_NN
        transduction_NN pathways_NNS are_VBP well-characterized_JJ in_IN a_DT wide_JJ
        variety_NN of_IN cell_NN types_NNS [_NN 8_CD 10_CD ]_NN ._. Insulin_NNP is_VBZ known_VBN to_TO
        primarily_RB transduce_NN its_PRP$ cellular_JJ actions_NNS via_IN two_CD signaling_VBG
        pathways_NNS ,_, the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP pathway_NN and_CC the_DT PI_NNP 3_CD -_: kinase_NN
        pathway_NN [_NN 8_CD 10_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP investigated_VBD
        the_DT signaling_VBG pathways_NNS that_WDT mediate_VB the_DT inhibitory_NN effects_NNS
        of_IN insulin_NN on_IN the_DT expression_NN of_IN the_DT SP-A_NNP genes_NNS in_IN human_JJ
        lung_NN epithelial_NN cells_NNS ._.
        Two_CD inhibitors_NNS of_IN PI_NNP 3_CD -_: kinase_NN ,_, wortmannin_NN and_CC LY_NNP 294002_CD ,_,
        and_CC an_DT inhibitor_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN activation_NN ,_, rapamycin_NN ,_,
        blocked_VBD the_DT inhibitory_NN effect_NN of_IN insulin_NN on_IN SP-A_NNP gene_NN
        expression_NN ._. We_PRP confirmed_VBD these_DT observations_NNS by_IN showing_VBG that_DT
        insulin_NN increased_VBD the_DT phosphorylation_NN of_IN a_DT specific_JJ
        rapamycin-sensitive_JJ residue_NN (_( threonine_NN 389_CD )_) ,_, present_JJ in_IN the_DT
        linker_NN region_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN ,_, a_DT phosphorylation_NN event_NN
        that_WDT is_VBZ known_VBN to_TO activate_VBP this_DT enzyme_NN [_NN 22_CD ]_NN ._. In_IN contrast_NN ,_,
        PD_NNP 98059_CD ,_, an_DT inhibitor_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP activation_NN ,_, did_VBD not_RB
        block_VB the_DT inhibitory_NN effects_NNS of_IN insulin_NN on_IN SP-A_NNP gene_NN
        expression_NN ._. In_IN addition_NN ,_, insulin_NN had_VBD no_DT effect_NN on_IN p_NN 44_CD /_NN 42_CD
        MAPK_NNP phosphorylation_NN during_IN a_DT 2_CD -_: hour_NN incubation_NN ._. The_DT
        effects_NNS of_IN the_DT PI_NNP 3_CD -_: kinase_NN and_CC the_DT MAPK_NNP pathway_NN inhibitors_NNS
        on_IN SP-A_NNP gene_NN expression_NN were_VBD evaluated_VBN using_VBG two_CD
        experimental_JJ models_NNS ,_, a_DT human_JJ immortalized_JJ epithelial_NN cell_NN
        line_NN (_( H_NNP 441_CD cells_NNS )_) and_CC human_JJ fetal_JJ lung_NN explants_NNS ._. We_PRP also_RB
        demonstrated_VBD that_DT transcriptional_NN inhibition_NN of_IN SP-A_NNP gene_NN
        commences_NNS within_IN 1_CD hour_NN of_IN exposure_NN to_TO the_DT hormone_NN ._.
        Together_RB ,_, our_PRP$ results_NNS are_VBP suggestive_JJ that_IN insulin_NN activates_NNS
        the_DT rapamycin-sensitive_JJ PI_NNP 3_CD -_: kinase_NN pathway_NN in_IN lung_NN
        epithelial_NN cells_NNS and_CC that_IN this_DT event_NN leads_VBZ to_TO an_DT inhibition_NN
        of_IN SP-A_NNP gene_NN transcription_NN ._.
        We_PRP found_VBD that_DT wortmannin_NN and_CC rapamycin_NN had_VBD no_DT effect_NN on_IN
        basal_NN SP-A_NNP mRNA_NN levels_NNS ,_, at_IN any_DT concentration_NN tested_VBN ._.
        However_RB ,_, PD_NNP 98059_CD ,_, added_VBD alone_RB ,_, abolished_VBN p_NN 44_CD /_NN 42_CD MAPK_NNP
        phosphorylation_NN in_IN control_NN cells_NNS and_CC also_RB inhibited_VBD basal_NN
        SP-A_NNP mRNA_NN levels_NNS in_IN a_DT dose-dependent_JJ manner_NN ._. We_PRP hypothesize_NN
        that_IN a_DT basal_NN level_NN of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP activity_NN may_MD be_VB required_VBN
        for_IN SP-A_NNP gene_NN expression_NN ._. Chess_NNP and_CC coworkers_NNS have_VBP shown_VBN
        that_IN transforming_VBG growth_NN factor-α_JJ and_CC hepatocyte_NN growth_NN
        factor_NN increase_NN the_DT phosphorylation_NN of_IN p_NN 44_CD /_NN p_NN 42_CD MAPK_NNP in_IN H_NNP 441_CD
        cells_NNS [_NN 23_CD ]_NN ._. Epidermal_NNP growth_NN factor_NN ,_, which_WDT binds_NNS to_TO the_DT
        same_JJ receptor_NN as_IN transforming_VBG growth_NN factor-α_JJ ,_, increases_NNS
        SP-A_NNP content_NN in_IN human_JJ fetal_JJ lung_NN [_NN 24_CD ]_NN ._. Hepatocyte_NNP growth_NN
        factor_NN has_VBZ also_RB been_VBN shown_VBN to_TO upregulate_NN the_DT synthesis_NN of_IN
        SP-A_NNP in_IN rat_NN type_NN II_NNP cells_NNS [_NN 25_CD ]_NN ._. Thus_RB ,_, phosphorylation_NN of_IN
        p_NN 44_CD /_NN 42_CD MAPK_NNP may_MD be_VB involved_VBN in_IN the_DT up-regulation_JJ of_IN SP-A_NNP
        gene_NN expression_NN ,_, results_NNS consistent_JJ with_IN our_PRP$ observation_NN
        that_DT inhibition_NN of_IN basal_NN levels_NNS of_IN p_NN 44_CD /_NN 42_CD MAPK_NNP
        phosphorylation_NN may_MD decrease_VB SP-A_NNP gene_NN expression_NN ._.
        In_IN summary_NN ,_, our_PRP$ studies_NNS are_VBP suggestive_JJ that_IN in_IN lung_NN
        epithelial_NN cells_NNS ,_, SP-A_NNP gene_NN transcription_NN is_VBZ inhibited_VBD by_IN
        insulin_NN via_IN the_DT rapamycin-sensitive_JJ PI_NNP 3_CD -_: kinase_NN pathway_NN ,_,
        but_CC not_RB the_DT p_NN 44_CD /_NN 42_CD MAPK_NNP pathway_NN ._. In_IN cultured_JJ human_JJ muscle_NN
        cells_NNS ,_, only_RB the_DT PI_NNP 3_CD -_: kinase_NN -_: p_NN 70_CD S_NNP 6_CD kinase_NN pathway_NN ,_, and_CC
        not_RB the_DT MAPK_NNP pathway_NN ,_, mediates_NNS insulin_NN up-regulation_JJ of_IN
        p_NN 85_CD α_NN PI_NNP 3_CD -_: kinase_NN gene_NN expression_NN [_NN 26_CD ]_NN ._. Similarly_RB ,_, in_IN L_NNP 6_CD
        myotubes_NNS ,_, insulin_NN induces_VBZ hexokinase_NN II_NNP gene_NN transcription_NN
        via_IN the_DT rapamycin-sensitive_JJ PI_NNP 3_CD -_: kinase_NN pathway_NN ,_, but_CC not_RB
        via_IN the_DT MAPK_NNP pathway_NN [_NN 27_CD ]_NN ._. The_DT PI_NNP 3_CD -_: kinase_NN -_: p_NN 70_CD S_NNP 6_CD
        kinase_NN pathway_NN ,_, but_CC not_RB the_DT MAPK_NNP pathway_NN ,_, mediates_NNS insulin_NN
        induction_NN of_IN glucose-_NN 6_CD -_: phosphate_NN dehydrogenase_NN gene_NN
        expression_NN in_IN primary_JJ rat_NN hepatocytes_NNS [_NN 28_CD ]_NN ._. In_IN H_NNP 411_CD E_NNP
        liver_NN cells_NNS ,_, insulin_NN down-regulates_JJ cAMP-induced_JJ
        phosphoenolpyruvate_NN carboxykinase_NN gene_NN transcription_NN via_IN
        the_DT PI_NNP 3_CD -_: kinase_NN pathway_NN ,_, but_CC not_RB via_IN the_DT MAPK_NNP pathway_NN [_NN 29_CD
        ]_NN ._. Phosphorylated_NNP p_NN 70_CD S_NNP 6_CD kinase_NN has_VBZ been_VBN shown_VBN to_TO be_VB
        present_JJ in_IN the_DT nucleus_NN in_IN insulin-treated_JJ cells_NNS [_NN 30_CD ]_NN ._.
        Moreover_RB ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT p_NN 70_CD S_NNP 6_CD kinase_NN
        phosphorylates_NNS and_CC activates_NNS members_NNS of_IN the_DT cAMP_NN response_NN
        element_NN modulator_NN family_NN of_IN transcription_NN factors_NNS [_NN 31_CD ]_NN ._.
        These_DT data_NNS raise_VBP the_DT possibility_NN that_DT transcriptional_NN
        regulation_NN of_IN SP-A_NNP gene_NN expression_NN occurs_VBZ via_IN the_DT PI_NNP
        3_CD -_: kinase_NN -_: p_NN 70_CD S_NNP 6_CD kinase_NN pathway_NN ._. Further_RB studies_VBZ will_MD be_VB
        required_VBN to_TO elucidate_NN the_DT function_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN in_IN the_DT
        nuclear_JJ events_NNS involved_VBN in_IN SP-A_NNP gene_NN transcription_NN ._.
      
      
        Conclusion_NNP
        Our_PRP$ studies_NNS are_VBP suggestive_JJ that_IN insulin_NN inhibits_NNS SP-A_NNP
        gene_NN transcription_NN via_IN the_DT PI_NNP 3_CD -_: kinase_NN pathway_NN in_IN lung_NN
        epithelial_NN cells_NNS ,_, specifically_RB via_IN the_DT rapamycin-sensitive_JJ
        activation_NN of_IN p_NN 70_CD S_NNP 6_CD kinase_NN ._. Insulin_NNP does_VBZ not_RB activate_VBP
        p_NN 44_CD /_NN 42_CD MAPK_NNP and_CC does_VBZ not_RB inhibit_VB SP-A_NNP gene_NN transcription_NN
        via_IN the_DT MAPK_NNP pathway_NN ._. Our_PRP$ findings_NNS further_JJ characterize_VB the_DT
        signal_NN transduction_NN pathways_NNS that_WDT control_NN surfactant_NN
        protein_NN gene_NN expression_NN ._. This_DT information_NN could_MD lead_VB to_TO the_DT
        possible_JJ modification_NN of_IN these_DT pathways_NNS by_IN pharmacological_JJ
        agents_NNS in_IN order_NN to_TO modulate_VBP the_DT composition_NN of_IN pulmonary_JJ
        surfactant_NN ,_, which_WDT is_VBZ critical_JJ for_IN normal_JJ respiratory_JJ
        function_NN and_CC for_IN host_NN defense_NN mechanisms_NNS in_IN the_DT lung_NN ._.
      
      
        Abbreviations_NNP
        ANOVA_NNP =_SYM analysis_NN of_IN variance_NN ;_: Erk_NNP =_SYM extracellular_NN
        signal-regulated_JJ kinase_NN ;_: IC_NNP 
        50_CD =_SYM half-maximal_JJ inhibition_NN ;_: IRS_NNP =_SYM
        insulin_NN receptor_NN substrate_NN ;_: LDH_NNP =_SYM lactate_NN dehydrogenase_NN ;_:
        MAPK_NNP =_SYM mitogen-activated_JJ protein_NN kinase_NN ;_: MEK_NNP =_SYM
        MAPK_NNP /_NN extracellular_NN signal-regulated_JJ kinase_NN kinase_NN ;_: mTOR_NN =_SYM
        mammalian_JJ target_NN of_IN rapamycin_NN ;_: PBS_NNP =_SYM phosphate-buffered_JJ
        saline_NN ;_: PI_NNP 3_CD -_: kinase_NN =_SYM phosphatidylinositol_NN 3_CD -_: kinase_NN ;_: RDS_NNP =_SYM
        respiratory_JJ distress_NN syndrome_NN ;_: SD_NNP =_SYM standard_JJ deviation_NN of_IN
        the_DT mean_NN ;_: SE_NNP =_SYM standard_JJ error_NN of_IN the_DT mean_NN ;_: SP_NNP =_SYM surfactant_NN
        protein_NN ;_: TPA_NNP =_SYM 12_CD -_: 
        
        O_NNP -_: tetradecanoylphorbol-_NN 13_CD -_: acetate_NN ._.
      
    
  
